Edition:
United States

Allergan plc (AGN)

AGN on New York Consolidated

192.25USD
9 Dec 2016
Change (% chg)

$3.78 (+2.01%)
Prev Close
$188.47
Open
$189.31
Day's High
$196.30
Day's Low
$189.13
Volume
5,378,130
Avg. Vol
4,342,994
52-wk High
$317.48
52-wk Low
$184.50

AGN

Chart for AGN

About

Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of pharmaceutical products, medical aesthetics, biosimilar and over-the-counter (OTC) pharmaceutical products. Its segments are US Brands, US Medical Aesthetics and International Brands. The US... (more)

Overall

Beta: 1.00
Market Cap(Mil.): $70,691.36
Shares Outstanding(Mil.): 375.08
Dividend: 0.70
Yield (%): 1.49

Financials

  AGN Industry Sector
P/E (TTM): -- 29.74 30.35
EPS (TTM): -4.94 -- --
ROI: -1.23 15.90 15.27
ROE: -2.48 17.00 16.60

Amgen, Allergan apply for European nod for Avastin biosimilar

Amgen Inc and Allergan Plc said they have submitted an application to the European health regulator seeking approval of their biosimilar version of Roche Holding AG's blockbuster cancer treatment, Avastin.

Dec 02 2016

Pfizer's Herceptin biosimilar succeeds in key breast cancer study

Pfizer Inc said on Wednesday its experimental biosimilar of Roche Holding AG's blockbuster breast cancer treatment Herceptin was found comparable with the branded version in a key study.

Nov 30 2016

BRIEF-Cipla says UK unit sells stake in Chase Pharmaceuticals

* Cipla EU divests stake in Chase Pharmaceuticals to Allergan

Nov 23 2016

BRIEF-Allergan completes acquisition of Chase Pharmaceuticals

* Allergan acquires Chase Pharmaceuticals to expand CNS research and development pipeline and build on commitment to alzheimer's disease

Nov 22 2016

BRIEF-Allergan receives FDA clearance for a new surgical treatment for refractory glaucoma

* Allergan receives FDA clearance for the xen gel stent, a new surgical treatment for refractory glaucoma

Nov 22 2016

BRIEF-Allergan received an additional approval from Health Canada for fibristal

* Allergan Plc - received an additional approval from Health Canada for fibristal Source text for Eikon: Further company coverage:

Nov 21 2016

BRIEF-Allergan announce study publication evaluating pelvic infection risk following same-day sexually transmitted infection testing, Liletta 52 mg placement

* Medicines360,Allergan announce study publication evaluating pelvic infection risk following same-day sexually transmitted infection testing, Liletta 52 mg placement

Nov 16 2016

BRIEF-Allergan announces partnership with Amy Dixon, Elite Paratriathlete

* Allergan announces partnership with Amy Dixon, Elite Paratriathlete, to improve patient-physician conversations about irritable bowel syndrome with diarrhea (ibs-d) Source text for Eikon: Further company coverage:

Nov 16 2016

BRIEF-Orexo says may appeal part of U.S. patent ruling

* Favorable outcome from Zubsolv patent infringement litigation against Actavis

Nov 16 2016

BRIEF-Amgen, Allergan submit biosimilar biologics license application for ABP 215 to U.S. FDA

* Amgen Inc - BLA submission includes analytical, pharmacokinetic and clinical data, as well as pharmacology and toxicology data

Nov 15 2016

Earnings vs. Estimates